Thomas Soloway
Direktor/Vorstandsmitglied bei THIRD HARMONIC BIO, INC.
Aktive Positionen von Thomas Soloway
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
THIRD HARMONIC BIO, INC. | Direktor/Vorstandsmitglied | 01.07.2022 | - |
Independent Dir/Board Member | 01.07.2022 | - | |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Vorstandsvorsitzender | 19.01.2021 | - |
T-Knife Therapeutics, Inc. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Thomas Soloway
Ehemalige bekannte Positionen von Thomas Soloway
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SATSUMA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 02.07.2020 | 08.06.2023 |
Independent Dir/Board Member | 02.07.2020 | 08.06.2023 | |
ASCENDIS PHARMA A/S | Finanzdirektor/CFO | 01.01.2014 | 01.09.2015 |
Investor Relations Kontakt | 01.01.2014 | 01.02.2019 | |
Public Communications Contact | 01.01.2014 | 01.02.2019 | |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Comptroller/Controller/Auditor | 01.02.2009 | 07.05.2012 |
Geschäftsführer | 01.02.2009 | 01.12.2013 | |
Finanzdirektor/CFO | 01.02.2009 | 07.05.2012 | |
Gründer | 01.01.2002 | 01.12.2013 | |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Direktor/Vorstandsmitglied | 30.01.2009 | 06.02.2009 |
Montreux Equity Partners, Inc.
Montreux Equity Partners, Inc. Investment ManagersFinance Montreux Equity Partners, Inc. (Montreux Equity Partners) is a Venture Capital firm founded in 1993 by Dan K. Turner. The firm is headquartered in San Francisco, California. | Corporate Officer/Principal | 01.01.1993 | - |
AUDENTES THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 29.09.2015 | 15.01.2020 |
Geschäftsführer | - | - | |
Finanzdirektor/CFO | 29.09.2015 | - | |
Treasurer | 15.01.2020 | - | |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
Ausbildung von Thomas Soloway
University of Southern California | Undergraduate Degree |
Georgetown University | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 11 |
Dänemark | 2 |
Deutschland | 2 |
Operativ
Chief Operating Officer | 3 |
Director of Finance/CFO | 3 |
Director/Board Member | 3 |
Sektoral
Health Technology | 9 |
Consumer Services | 3 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
ASCENDIS PHARMA A/S | Health Technology |
PARATEK PHARMACEUTICALS, INC. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Montreux Equity Partners, Inc.
Montreux Equity Partners, Inc. Investment ManagersFinance Montreux Equity Partners, Inc. (Montreux Equity Partners) is a Venture Capital firm founded in 1993 by Dan K. Turner. The firm is headquartered in San Francisco, California. | Finance |
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Health Technology |
T-Knife Therapeutics, Inc. |
- Börse
- Insiders
- Thomas Soloway
- Erfahrung